A Phase 3 interventional study of rimonabant (SR141716) and placebo in Obesity, sponsored by Sanofi. Terminated at 1 site in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2009-07-20.
Sponsored by Sanofi · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies testing rimonabant in Obesity — none open to participants now, none under way, none of them phase 3. Rimonabant · Obesity.
Among the 21 studies testing rimonabant in Obesity, this one is the 7th largest by enrollment, is one of 6 that started in 2007, is one of 18 in phase 3, and was the 12th registered.
11,547 studies on the registry are indexed under Obesity; 2,050 are open to participants now.
Browse Obesity studies →None of the 21 studies testing rimonabant in Obesity is open now. The open studies under Obesity, anywhere →
Rimonabant: first EMA approval 2006. What it is approved for, and how studies give it, is on its page →
Of the 1,343 Obesity studies recruiting now, 377 (28%) set no upper age limit and 862 (64%) stop at 75 or younger; 168 take children under 18; 488 take healthy volunteers.
This study: 20 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
First in 2001; this study’s year is marked. 6 started in 2007.
This study's enrollment of 915 is above the median of 67 across 9,027 interventional studies indexed under Obesity.
Median enrollment 643 across the 21 interventional studies. Of the 21 that completed or were terminated, 1 (5%) have results posted.
This tab as a report to print or save as PDF → With an account.
19 of 21 have an industry lead sponsor. The 3 most frequent:
Sanofi is the lead sponsor of 1,559 studies on the registry; 90 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 123 (60%) have results posted.
21 studies in Obesity by Sanofi: none open now, none under way, none of them phase 3. Of 21 finished, 0 (0%) have results posted.
Among the 21 studies in Obesity by Sanofi, this one is the 7th largest by enrollment, is one of 4 that started in 2007, is one of 18 in phase 3, and was the 14th registered.
Sanofi’s Obesity studies by the year they started, since 2001.
None of the studies under way reaches primary completion within a year.
Among the 21 studies testing rimonabant in Obesity, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Sanofi’s 21 in Obesity:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The primary objective of this study is to assess the efficacy of SR141716 compared to placebo on body weight and triglycerides changes over a period of 52 weeks.
Secondary objectives are:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
At least 1 criteria of the following 2 comorbidities:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: rimonabant (SR141716)
Drug: placebo
oral administration once daily
oral administration once daily
body weight: relative change from baseline
Time frame: Week 52
triglycerides: relative change from baseline
Time frame: Week 52
HDL-cholesterol ;visceral fat area
Time frame: Week 52
Safety: Adverse events
Time frame: study period
The record gives a start of Feb 2007, a primary completion of Nov 2008 and a completion of Feb 2009. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jul 2009. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Rimonabant